Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
J Alzheimers Dis. 2022;88(2):455-458. doi: 10.3233/JAD-220190.
Three decades with the amyloid hypothesis, nearly two with amyloid-PET imaging, and one with testing of anti-amyloid therapy have not yielded benefits to patients with Alzheimer's disease (AD). It is time to focus on more promising options, e.g., infection, low dose radiation, and atherosclerosis. The relevance of the latter in managing AD has fluctuated from being significant to insignificant. Current methodologies for detecting cerebral atherosclerosis reflect advanced changes in only major arteries. In contrast, 18F-sodium fluoride PET imaging assessing early-stage cerebral atherosclerosis regionally or in the entire vascular bed may provide new insight in this age-related process in dementia.
三十年的淀粉样蛋白假说，近二十年的淀粉样蛋白-PET 成像，以及一项抗淀粉样蛋白治疗测试，都没有给阿尔茨海默病（AD）患者带来益处。现在是时候关注更有前途的选择了，例如感染、低剂量辐射和动脉粥样硬化。后者在 AD 管理中的相关性从显著到不显著波动。目前用于检测脑动脉粥样硬化的方法仅反映了主要动脉的晚期变化。相比之下，18F-氟化钠 PET 成像评估早期脑动脉粥样硬化区域或整个血管床可能为痴呆相关过程提供新的见解。
